386 related articles for article (PubMed ID: 15905968)
21. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
22. First-line therapeutic strategies in metastatic colorectal cancer.
Davies JM; Goldberg RM
Oncology (Williston Park); 2008 Nov; 22(13):1470-9. PubMed ID: 19133603
[TBL] [Abstract][Full Text] [Related]
23. [Transition of chemotherapy for metastatic colorectal cancer and recent advances].
Muro K
Nihon Rinsho; 2010 Jun; 68(6):1143-9. PubMed ID: 20535969
[TBL] [Abstract][Full Text] [Related]
24. A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.
Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Lee SS; Kim MK; Sym SJ; Lee JS; Kang YK
J Korean Med Sci; 2007 Sep; 22 Suppl(Suppl):S98-S103. PubMed ID: 17923763
[TBL] [Abstract][Full Text] [Related]
25. [The development of the first line treatment of metastatic colorectal cancer (mCRC)].
Landherr L; Nagykálnai T
Magy Onkol; 2009 Sep; 53(3):237-46. PubMed ID: 19793687
[TBL] [Abstract][Full Text] [Related]
26. Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.
Uehara K; Ishiguro S; Hiramatsu K; Nishio H; Takeuchi E; Takahari D; Yoshioka Y; Takahashi Y; Ebata T; Yoshimura K; Muro K; Nagino M
Jpn J Clin Oncol; 2011 Oct; 41(10):1229-32. PubMed ID: 21840871
[TBL] [Abstract][Full Text] [Related]
27. New developments in systemic chemotherapy in advanced colorectal cancer.
Cats A
Scand J Gastroenterol Suppl; 2003; (239):78-86. PubMed ID: 14743888
[TBL] [Abstract][Full Text] [Related]
28. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
[TBL] [Abstract][Full Text] [Related]
29. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
Chu E
Clin Colorectal Cancer; 2008 Jul; 7(4):226. PubMed ID: 18650190
[No Abstract] [Full Text] [Related]
30. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
Cremolini C; Milione M; Marmorino F; Morano F; Zucchelli G; Mennitto A; Prisciandaro M; Lonardi S; Pellegrinelli A; Rossini D; Bergamo F; Aprile G; Urbani L; Morelli L; Schirripa M; Cardellino GG; Fassan M; Fontanini G; de Braud F; Mazzaferro V; Falcone A; Pietrantonio F
Br J Cancer; 2018 Apr; 118(7):955-965. PubMed ID: 29531324
[TBL] [Abstract][Full Text] [Related]
31. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
Bokemeyer C; Bondarenko I; Makhson A; Hartmann JT; Aparicio J; de Braud F; Donea S; Ludwig H; Schuch G; Stroh C; Loos AH; Zubel A; Koralewski P
J Clin Oncol; 2009 Feb; 27(5):663-71. PubMed ID: 19114683
[TBL] [Abstract][Full Text] [Related]
32. Systemic therapy for colorectal cancer.
Meyerhardt JA; Mayer RJ
N Engl J Med; 2005 Feb; 352(5):476-87. PubMed ID: 15689586
[No Abstract] [Full Text] [Related]
33. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
[TBL] [Abstract][Full Text] [Related]
34. Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
Hwang JJ
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):26-34. PubMed ID: 15685831
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
[TBL] [Abstract][Full Text] [Related]
36. Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.
Sunakawa Y; Bekaii-Saab T; Stintzing S
Cancer Treat Rev; 2016 Apr; 45():97-104. PubMed ID: 27002945
[TBL] [Abstract][Full Text] [Related]
37. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
Malik Z; Eng C
Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
[No Abstract] [Full Text] [Related]
38. [Bevacizumab in the treatment of colorectal carcinoma: news from ASCO 2008].
Mansueto G; Longo F
Tumori; 2008; 94(4):suppl 1-14. PubMed ID: 18822711
[No Abstract] [Full Text] [Related]
39. Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
Maung K; Lee D; DeGrendele HC; Schilsky R; Chu E; Jain VK; Copur S
Clin Colorectal Cancer; 2002 Nov; 2(3):140-5. PubMed ID: 12482329
[No Abstract] [Full Text] [Related]
40. [Advances in the treatment of metastatic colorectal cancer with bevacizumab].
Longo F; Mansueto G
Tumori; 2006; 92(5):suppl 1-12. PubMed ID: 17168449
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
